Dorsal Sural Nerve Test Sensitive to Oxaliplatin NeuropathyDorsal Sural Nerve Test Sensitive to Oxaliplatin Neuropathy
Dorsal sural nerve conduction testing is a moderately sensitive and very specific test for early detection of oxaliplatin-induced peripheral neuropathy and beats sural nerve testing. Medscape Medical News
Publication date: Available online 13 October 2018Source: Neuroscience ResearchAuthor(s): Lei Wang, Michael Chopp, Alexandra Szalad, XueRong Lu, Mei Lu, Talan Zhang, Zheng Gang ZhangAbstractAngiopoietin-1 (Ang1) and its receptor Tie2 regulate vascular function. Our previous study demonstrated that thymosin beta 4 (Tβ4) ameliorates neurological function of diabetic peripheral neuropathy. Mechanisms underlying the therapeutic effect of Tβ4 on diabetic peripheral neuropathy have not been fully investigated. The present in vivo study investigated whether the Ang1/Tie2 signaling pathway is involved in Tβ4-improve...
Eculizumab may be effective in reversing neurologic symptoms of inherited CD59 deficiency.
Abstract Learning to recognize the various clinical and electrodiagnostic patterns of peripheral neuropathy enables a targeted approach to etiologic investigation, and subsequently guides patient discussions of self-management, disease course, and prognosis. Moreover, as advancements in neuropathology and pharmacotherapy inform the many etiologies of polyneuropathy, it is imperative for clinicians to identify the underlying etiology to appropriately guide treatment options and prevent complications. PMID: 30293629 [PubMed - in process]
AbstractIntroductionEarly detection of diabetic peripheral neuropathy (DPN) is critical in patients with type 2 diabetes mellitus (T2DM) due to the lack of targeted therapy for DPN. We have investigated the relationship between different stages of diabetic nephropathy and DPN in an attempt to elucidate whether albuminuria can be used as an early warning signal of DPN progression.MethodsA total of 217 T2DM patients who met the inclusion criteria were recruited from the Department of Endocrinology, Nanfang Hospital between January 2016 and June 2016. These patients were placed in groups based on urinary albumin excretion rat...
NEW YORK (Reuters Health)—A large epidemiological study provides more evidence of a link between tumor necrosis factor inhibitors (TNFi) and peripheral neuropathy (PN). “These events are rare and the benefit of these drugs still outweigh this risk so this should not change practice,” cautions first author Dr. Mahyar Etminan from the University of British Columbia... [Read More]
Journal of Neurochemistry,Volume 0, Issue ja, -Not available-.
CONCLUSIONS: A non-weightbearing exercise program for people with diabetes, severe peripheral neuropathy and foot ulcers seems feasible and safe. Further studies are needed to confirm these findings. Implications for rehabilitation An exercise program designed for people with severe peripheral neuropathy and diabetic foot ulcers can be safe by means of not compromising healing of foot ulcers. Feasible in terms of attendance and progression. An alternative to passive waiting for ulcer to heal in a population already deconditioned. PMID: 30293458 [PubMed - as supplied by publisher]
CONCLUSION: The severity of CIPN symptoms was the most important predictor of LUTS. Nurses' care for advanced cancer patients should incorporate a comprehensive health assessment, which includes a history of treatment and physical neuropathic symptoms, for any patient complaining of CIPN symptoms. PMID: 30286582 [PubMed]
CONCLUSIONS: We can hypothesize that the IgG passage through the blood-brain barrier could have contributed to the cause of TIAs, through a mechanism involving the precipitation of circulating immune complexes formed by the two subclasses in the intrathecal vessels. PMID: 30280791 [PubMed - in process]
Publication date: November 2018Source: Pharmacological Research, Volume 137Author(s): Francesca Punzo, Chiara Tortora, Daniela Di Pinto, Elvira Pota, Maura Argenziano, Alessandra Di Paola, Fiorina Casale, Francesca RossiAbstractOsteosarcoma is the most common primary malignant tumor of bone in children and adolescents.Bortezomib (BTZ) is an approved anticancer drug, classified as a selective reversible inhibitor of the ubiquitin-dependent proteasome system, that leads to cancer cell cycle arrest and apoptosis reducing the invasion ability of Osteosarcoma cells in vitro. It also regulates the RANK/RANKL/OPG system, involved...